- The Wall Street Journal•2 hours ago
GlaxoSmithKline is pinning the future of its HIV business on an audacious bet: upending the decades-old triple-drug treatment strategy that has turned a fatal illness into a chronic condition.
- Motley Fool•18 hours ago
George Soros' namesake fund dumped its entire holdings in the iShares Nasdaq Biotechnology Index Fund, Gilead Sciences, and Novavax.
Biotech is one of the sectors where M&A activities never stop, as the potential for growth and development is immense. After the termination of a $160 billion merger with Allergan plc Ordinary Shares (NYSE: ...
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||79.63 x 700|
|Ask||79.77 x 200|
|Day's Range||79.27 - 80.33|
|52wk Range||77.92 - 113.31|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||7.00|
|Avg Vol (3m)||10,159,655|
|Dividend & Yield||1.88 (2.36%)|